## **Oncology Injectable and Infused Medication Enrollment Form**



Fax Referral To: 1-800-323-2445 Email Referral To: customerservicefax@caremark.com Phone: 1-800-237-2767

Six Simple Steps to Submitting a Referral **1 PATIENT INFORMATION** (Complete or include demographic sheet) \_\_\_\_City, State, ZIP: \_\_ Address: Preferred Contact Methods: Phone (to primary # provided below) Text (to cell # provided below) Email (to email provided below) Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone. Primary Phone: \_\_\_\_\_ Alternate Phone: \_\_\_\_ DOB: \_\_\_\_ Gender: \_ Male \_ Female Email: \_\_\_\_ Last Four of SSN: \_\_\_\_ Primary Language: \_\_\_\_ 2 PRESCRIBER INFORMATION 
 Prescriber's Name:
 \_\_\_\_\_ State License #:

 NPI #:
 \_\_\_\_\_ DEA #:
 \_\_\_\_\_ Group or Hospital:
 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back) 4 DIAGNOSIS AND CLINICAL INFORMATION Needs by Date: \_\_\_\_\_ Ship to: Datient Office Other: \_\_\_\_\_ Diagnosis (ICD-10): Code: \_\_\_\_\_ Description \_\_\_\_ Code: \_\_\_\_ Description \_\_\_\_\_ Per additional ICD-10 information, please visit CVS Specialty Healthcare Professionals Website https://www.cvsspecialty.com/wps/portal/specialty/healthcare-professionals/about-us Patient Clinical Information: Weight: \_\_\_\_lb/kg Height: \_\_\_\_in/cm BSA: \_\_\_\_\_ m<sup>2</sup> Allergies: \_\_\_ 5 PRESCRIPTION INFORMATION Medications: ☐ Poteligeo™ (mogamulizumab) ☐ Abraxane® (paclitaxel) ☐ Herceptin® (trastuzumab) ☐ Rituxan® (rituximab)
☐ Rituxan Hycela® (rituximab and hyaluronidase ☐ Alimta® (pemetrexed) ☐ Keytruda® (pembrolizumab) ☐ Lumoxiti® (moxetumomab) ☐ Avastin® (bevacizumab) human) injection ☐ Besponsa® (inotuzumab ozogamicin) ☐ Mylotarg<sup>™</sup> (gemtuzumab ozogamicin) ☐ Sarclisa® (isatuximab-irfc) Nyvepria™ (pegfilgrastim-apgf) ☐ Docetaxel ☐ Vectibix ® (panitumumab) ☐ Opdivo™ (nivolumab) ☐ Enhertu® (fam-trastuzumab deruxtecan-nxki) ☐ Velcade® (bortezomib)
☐ Yervoy® (ipilimumab) ☐ Erwinaze® (asparaginase *Erwinia* ☐ Padcev<sup>™</sup> (enfortumab vedotin-ejfv) chrysanthemi) Zoledronic Acid ☐ Phesgo (pertuzumab, trastuzamab, and ☐ Gamcitabine HCL Other: hvaluronidase-zzxf) SIG/DIRECTIONS DRUG NAME/STRENGTH QUANTITY/REFILLS **PRESCRIPTIONS** RX 1 Other: Refills: Quantity: RX 2 ☐ Other: \_\_\_\_\_ Refills:\_\_\_\_\_ Quantity: Other: \_\_\_ ☐ Other: RX 3 Refills: STAMP SIGNATURE NOT ALLOWED ☐ Patient is interested in patient support programs 6 PHYSICIAN SIGNATURE REQUIRED PRODUCT SUBSTITUTION PERMITTED DISPENSE AS WRITTEN (Date)

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.

©2020 CVS Specialty and/or one of its affiliates. 75-44095A 072120